| Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer NICE TA389 | Paclitaxel, Pegylated liposomal doxorubicin, Gemcitabine, Trabectedin, Topotecan | Recommended Not recommended | 27 Apr 2016 | Current |
| Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction NICE TA388 | Sacubitril / Valsartan | Optimised | 27 Apr 2016 | Current |
| Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated NICE TA387 | Abiraterone acetate | Recommended | 27 Apr 2016 Updated 27 Jul 2016 | Current |
| Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis NICE TA386 | Ruxolitinib | Optimised | 23 Mar 2016 | Current |
| Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia NICE TA385 | Ezetimibe | Recommended | 24 Feb 2016 | Current |
| Nivolumab for treating advanced (unresectable or metastatic) melanoma NICE TA384 | Nivolumab | Recommended | 18 Feb 2016 | Current |
| TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis NICE TA383 | Adalimumab, Certolizumab Pegol, Etanercept, Golimumab, Infliximab | Recommended | 1 Feb 2016 | Current |
| Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) NICE TA382 | Eltrombopag | Terminated (no company submission) | 27 Jan 2016 | Current |
| Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy NICE TA381 | Olaparib | Optimised | 27 Jan 2016 | Current |
| Panobinostat for treating multiple myeloma after at least 2 previous treatments NICE TA380 | — | Recommended | 27 Jan 2016 | Current |
| Nintedanib for treating idiopathic pulmonary fibrosis NICE TA379 | Nintedanib | Optimised | 27 Jan 2016 | Current |
| Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy NICE TA378 | — | Not recommended | 27 Jan 2016 | Current |
| Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated NICE TA377 | Enzalutamide | Recommended | 27 Jan 2016 | Current |
| Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases NICE TA376 | — | Optimised | 27 Jan 2016 | Replaced by TA412 |
| Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed NICE TA375 | Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Tocilizumab, Abatacept | Optimised | 26 Jan 2016 | Current |
| Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy NICE TA374 | Erlotinib, Gefitinib | Optimised Not recommended | 16 Dec 2015 | Current |
| Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis NICE TA373 | Abatacept, Adalimumab, Etanercept, Tocilizumab | Recommended | 16 Dec 2015 | Current |
| Apremilast for treating active psoriatic arthritis NICE TA372 | — | Not recommended | 16 Dec 2015 | Replaced by TA433 |
| Trastuzumab emtansine for treating HER2-positive, unresectable locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane NICE TA371 | Trastuzumab emtansine | Not recommended | 16 Dec 2015 | Current |
| Bortezomib for previously untreated mantle cell lymphoma NICE TA370 | Bortezomib | Recommended | 16 Dec 2015 | Current |
| Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears NICE TA369 | Ciclosporin | Recommended | 16 Dec 2015 | Current |
| Apremilast for treating moderate to severe plaque psoriasis NICE TA368 | Apremilast | Not recommended | 25 Nov 2015 | Current |
| Vortioxetine for treating major depressive episodes NICE TA367 | Vortioxetine | Recommended | 25 Nov 2015 | Current |
| Pembrolizumab for advanced melanoma not previously treated with ipilimumab NICE TA366 | Pembrolizumab | Recommended | 25 Nov 2015 Updated 12 Sep 2017 | Current |
| Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C NICE TA365 | Ritonavir | Recommended | 25 Nov 2015 | Current |
| Daclatasvir for treating chronic hepatitis C NICE TA364 | — | Optimised | 25 Nov 2015 | Withdrawn |
| Ledipasvir–sofosbuvir for treating chronic hepatitis C NICE TA363 | — | Optimised | 25 Nov 2015 | Current |
| Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) NICE TA362 | — | Terminated (no company submission) | 28 Oct 2015 | Current |
| Simeprevir in combination with sofosbuvir for treating genotype 1 or 4 chronic hepatitis C (terminated appraisal) NICE TA361 | — | Terminated (no company submission) | 28 Oct 2015 | Current |
| Paclitaxel as albumin-bound nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic cancer NICE TA360 | — | Not recommended | 28 Oct 2015 | Current |
| Idelalisib for treating chronic lymphocytic leukaemia NICE TA359 | Idelalisib | Recommended | 28 Oct 2015 | Current |
| Tolvaptan for treating autosomal dominant polycystic kidney disease NICE TA358 | Tolvaptan | Optimised | 28 Oct 2015 | Current |
| Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab NICE TA357 | Pembrolizumab | Recommended | 7 Oct 2015 Updated 12 Sep 2017 | Current |
| Ruxolitinib for treating polycythaemia vera (terminated appraisal) NICE TA356 | Ruxolitinib | Terminated (no company submission) | 23 Sep 2015 | Current |
| Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation NICE TA355 | Edoxaban | Recommended | 23 Sep 2015 Updated 2 Jul 2021 | Current |
| Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism NICE TA354 | Edoxaban | Recommended | 26 Aug 2015 | Current |
| Bevacizumab for treating relapsed, platinum‑resistant epithelial ovarian, fallopian tube or primary peritoneal cancer (terminated appraisal) NICE TA353 | Bevacizumab | Terminated (no company submission) | 26 Aug 2015 | Current |
| Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy NICE TA352 | Vedolizumab | Optimised | 26 Aug 2015 | Current |
| Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal) NICE TA351 | Cangrelor | Terminated (no company submission) | 22 Jul 2015 | Current |
| Secukinumab for treating moderate to severe plaque psoriasis NICE TA350 | Secukinumab | Recommended | 22 Jul 2015 | Current |
| Dexamethasone intravitreal implant for treating diabetic macular oedema NICE TA349 | Dexamethasone | Optimised | 22 Jul 2015 | Replaced by TA824 |
| Everolimus for preventing organ rejection in liver transplantation NICE TA348 | Everolimus | Not recommended | 22 Jul 2015 | Current |
| Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer NICE TA347 | Nintedanib | Recommended | 22 Jul 2015 | Current |
| Aflibercept for treating diabetic macular oedema NICE TA346 | Aflibercept | Optimised | 22 Jul 2015 | Current |
| Naloxegol for treating opioid‑induced constipation NICE TA345 | — | Recommended | 22 Jul 2015 | Current |
| Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia NICE TA344 | Ofatumumab | Recommended | 2 Jun 2015 | Withdrawn |
| Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia NICE TA343 | Obinutuzumab | Optimised | 2 Jun 2015 | Current |
| Vedolizumab for treating moderately to severely active ulcerative colitis NICE TA342 | Vedolizumab | Recommended | 5 Jun 2015 | Current |
| Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism NICE TA341 | Apixaban | Recommended | 4 Jun 2015 | Current |
| Ustekinumab for treating active psoriatic arthritis NICE TA340 | Ustekinumab | Optimised | 4 Jun 2015 Updated 3 Mar 2017 | Current |
| Omalizumab for previously treated chronic spontaneous urticaria NICE TA339 | Omalizumab | Optimised | 8 Jun 2015 | Current |
| Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib NICE TA338 | Pomalidomide | Not recommended | 25 Mar 2015 | Current |
| Rifaximin for preventing episodes of overt hepatic encephalopathy NICE TA337 | Rifaximin | Recommended | 25 Mar 2015 | Current |
| Empagliflozin in combination therapy for treating type 2 diabetes NICE TA336 | — | Recommended | 25 Mar 2015 | Current |
| Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome NICE TA335 | Rivaroxaban | Recommended | 25 Mar 2015 | Current |
| Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal) NICE TA334 | Regorafenib | Terminated (no company submission) | 25 Feb 2015 | Current |
| Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment NICE TA333 | Axitinib | Recommended | 25 Feb 2015 | Current |
| Sipuleucel-T for treating asymptomatic or minimally symptomatic metastatic hormone-relapsed prostate cancer NICE TA332 | — | Not recommended | 23 Feb 2015 | Current |
| Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C NICE TA331 | — | Recommended | 25 Feb 2015 | Current |
| Sofosbuvir for treating chronic hepatitis C NICE TA330 | — | Optimised | 25 Feb 2015 | Current |
| Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy NICE TA329 | Infliximab, Adalimumab, Golimumab | Recommended | 25 Feb 2015 | Current |
| Idelalisib for treating follicular lymphoma that is refractory to 2 prior treatments (terminated appraisal) NICE TA328 | Idelalisib | Terminated (no company submission) | 17 Dec 2014 | Replaced by TA604 |
| Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism NICE TA327 | Dabigatran Etexilate | Recommended | 17 Dec 2014 | Current |
| Imatinib for the adjuvant treatment of gastrointestinal stromal tumours NICE TA326 | Imatinib | Recommended | 26 Nov 2014 | Current |
| Nalmefene for reducing alcohol consumption in people with alcohol dependence NICE TA325 | — | Recommended | 26 Nov 2014 | Current |
| Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block NICE TA324 | — | Recommended | 26 Nov 2014 | Current |
| Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy NICE TA323 | — | Recommended | 26 Nov 2014 | Current |
| Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality NICE TA322 | Lenalidomide | Recommended | 24 Sep 2014 Updated 26 Jun 2019 | Current |
| Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma NICE TA321 | Dabrafenib | Recommended | 22 Oct 2014 | Current |
| Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis NICE TA320 | Dimethyl Fumarate | Recommended | 27 Aug 2014 | Current |
| Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma NICE TA319 | Ipilimumab | Recommended | 23 Jul 2014 | Current |
| Lubiprostone for treating chronic idiopathic constipation NICE TA318 | Lubiprostone | Recommended | 23 Jul 2014 | Withdrawn |
| Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes NICE TA317 | Prasugrel | Recommended | 23 Jul 2014 | Current |
| Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen NICE TA316 | Enzalutamide | Recommended | 23 Jul 2014 | Current |
| Canagliflozin in combination therapy for treating type 2 diabetes NICE TA315 | Canagliflozin | Recommended | 25 Jun 2014 | Current |
| Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure NICE TA314 | — | Optimised | 25 Jun 2014 | Current |
| Ustekinumab for treating active psoriatic arthritis NICE TA313 | — | Not recommended | 27 May 2014 | Replaced by TA340 |
| Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis NICE TA312 | Alemtuzumab | Recommended | 28 May 2014 Updated 21 May 2024 | Current |
| Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation NICE TA311 | Bortezomib | Recommended | 23 Apr 2014 | Current |
| Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer NICE TA310 | Afatinib | Recommended | 23 Apr 2014 | Current |
| Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer NICE TA309 | Pemetrexed | Not recommended | 23 Apr 2014 | Replaced by TA402 |
| Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis NICE TA308 | Rituximab | Optimised | 26 Mar 2014 | Current |
| Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy NICE TA307 | Aflibercept | Not recommended | 25 Mar 2014 | Current |
| Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma NICE TA306 | — | Optimised | 26 Feb 2014 | Current |
| Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion NICE TA305 | Aflibercept | Recommended | 26 Feb 2014 | Current |
| Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip NICE TA304 | — | Recommended | 26 Feb 2014 | Current |
| Teriflunomide for treating relapsing–remitting multiple sclerosis NICE TA303 | Teriflunomide | Recommended | 22 Jan 2014 Updated 1 Jun 2014 | Current |
| Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal) NICE TA302 | — | Terminated (no company submission) | 27 Nov 2013 | Current |
| Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy NICE TA301 | — | Optimised | 27 Nov 2013 | Replaced by TA953 |
| Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people NICE TA300 | — | Recommended | 27 Nov 2013 | Current |
| Bosutinib for previously treated chronic myeloid leukaemia NICE TA299 | Bosutinib | Not recommended | 27 Nov 2013 | Replaced by TA401 |
| Ranibizumab for treating choroidal neovascularisation associated with pathological myopia NICE TA298 | Ranibizumab | Recommended | 27 Nov 2013 Updated 20 May 2024 | Current |
| Ocriplasmin for treating vitreomacular traction NICE TA297 | — | Optimised | 23 Oct 2013 | Current |
| Crizotinib for previously treated non-small-cell lung cancer associated with an anaplastic lymphoma kinase fusion gene NICE TA296 | Crizotinib | Not recommended | 25 Sep 2013 | Current |
| Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy NICE TA295 | Everolimus | Not recommended | 28 Aug 2013 | Current |
| Aflibercept solution for injection for treating wet age‑related macular degeneration NICE TA294 | Aflibercept | Recommended | 24 Jul 2013 | Current |
| Eltrombopag for treating chronic immune thrombocytopenia NICE TA293 | Eltrombopag | Optimised | 24 Jul 2013 Updated 26 Oct 2018 | Current |
| Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder NICE TA292 | Aripiprazole | Recommended | 24 Jul 2013 | Current |
| Pegloticase for treating severe debilitating chronic tophaceous gout NICE TA291 | — | Not recommended | 26 Jun 2013 | Current |
| Mirabegron for treating symptoms of overactive bladder NICE TA290 | Mirabegron | Optimised | 26 Jun 2013 | Current |
